Tirzepatide 10mg
Longevity
$169
Dual GLP-1/GIP receptor agonist for metabolic optimization, appetite regulation, and body composition improvement.
Overview
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity, tirzepatide demonstrated up to 22.5% weight reduction in the SURMOUNT-1 trial. Its dual mechanism provides complementary metabolic benefits that surpass GLP-1 agonism alone.
Lab Results — 10mg
Every batch is independently tested. Results below are from the Certificate of Analysis for the 10mg batch.
Scientific Details
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
~4.8 kDa
Form
Lyophilized peptide powder
Solubility
Soluble in bacteriostatic water
Dosage Range
2.5–15mg weekly (research context)
Plasma Half-Life
~5 days
Bioavailability
~80% subcutaneous
Resources
Key peer-reviewed studies supporting the efficacy and safety of this compound.
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
Jastreboff A.M. et al. — New England Journal of Medicine (2022)
Key FindingTirzepatide produced a mean weight reduction of up to 22.5% over 72 weeks in adults with obesity, significantly exceeding placebo.
Dual GIP and GLP-1 receptor agonist tirzepatide improves glycemic control
Frias J.P. et al. — Lancet (2021)
Key FindingTirzepatide demonstrated superior HbA1c reduction and weight loss compared to semaglutide in a head-to-head Phase 3 trial.
GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea
Samms R.J. et al. — Diabetes (2020)
Key FindingCo-activation of GIP receptors reduced the nausea side-effect profile of GLP-1 agonism while preserving or enhancing metabolic benefits.